BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
A total of 300 new bisphosphonates were screened for their effect on bone resorption in the rat. Among these, 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate (BM 21.0955) was selected for detailed investigation. It inhibited arotinoid-stimulated bone resorption as assessed by calcemia in thyroparathyroid-ectomized rats at a SC dose as low as 0.001 mg P (0.016 μmol) per kg body weight per day. The compound was thus about 2, 10, 50, and 500 times more potent than risedronate, alendronate, pamidronate, and clodronate, respectively. Intravenous administration was as effective as subcutaneous, and oral administration was 100 times less effective. The effect after one administration decreased with time but was still measurable after 2 weeks. Nonstimulated bone resorption assayed by the urinary excretion of radiolabeled tetracycline from lifelong prelabeled animals was also inhibited. This effect started 3 days after a single dose and was still maximal after 7 days. Histomorphometric analysis of the tibial metaphysis in growing intact rats also showed an inhibition of bone resorption along with an increase in bone mass. The number of osteoclasts increased in animals treated with 0.01 and 0.1 mg P per kg (0.16 and 1.6 μmol/kg) body weight SC but decreased in animals given 1 mg P per kg (16.1 μmol/kg), showing that the inhibition of bone resorption was not due to an inhibition of osteoclast recruitment. No inhibition of mineralization occurred. This new bisphosphonate appears to have great potential for use in human bone disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bisphosphonates do not appear to suppress osteoclastogenesis (129, 140, 141)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [141]
Citations
Cites
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sorensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 935
Fleisch, H., Graham, R., Russell, G., & Francis, M. D. (1969) · Science · doi:10.1126/science.165.3899.1262 · Cited by 758
Self-citationHandbook of Experimental Pharmacology
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-1-269_2 · Cited by 727
Francis, M. D., Graham, R., Russell, G., & Fleisch, H. (1969) · Science · doi:10.1126/science.165.3899.1264 · Cited by 608
Self-citationThe Role of Phosphonates in Living Systems
Hilderbrand (2018) · CRC Press eBooks · doi:10.1201/9781351076470 · Cited by 544
Brown, W. A. B. (1985) · FEBS Letters · doi:10.1016/0014-5793(85)81367-3 · Cited by 495
Schenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Self-citationTwo modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Russell, R. G. G., Mühlbauer, R. C., Bisaz, S., Williams, D. A., & Fleisch, H. (1970) · Calcified Tissue Research · doi:10.1007/bf02196199 · Cited by 341
Self-citation
Research works printed but not linked: 8
- Kanis, 1987, Clodronate – a new perspective in the treatment of neoplastic bone disease, Bone (Suppl.), 8, S1
- Burckhardt, 1989, Disodium Pamidronate (APD) in the Treatment of Malignancy-Related Disorders
- Charhon, 1986, Histomorphometric analysis of bone biopsies of baboons treated with “SR 41319BH,” a new diphosphonate (abstract), Calcif Tissue Int, 38, 124
- Bevan, 1988, Bisphosphonate action in the oophorectomized rat: The effects of 2-(3-pyridinyl)-1-hydroxyethylidene-bis(phosphonate) on skeletal metabolism; comparison with etidronate (abstract), J Bone Miner Res (Suppl.), 3, 498
- Valentin-Opran, 1990, Risedronate: Preliminary results of a pharmacologic study in pagetic patients. Twelfth Annual Meeting of the American Society for Bone and Mineral Research, Atlanta, Georgia, August 28–31, 1990 (abstract 182), J Bone Miner Res, 5
- Mühlbauer, 1990, A method for continual monitoring of bone resorption in the rat: Evidence for a diurnal rhythm, Am J Physiol, 259, R679
- Schenk, 1984, Methods of Calcified Tissue Preparation, 1
- Mühlbauer, 1989, 1-Hydroxy-3-(methylpentyl-amino)propylidene-bisphosphonate (BM 21.0955), a potent new inhibitor of bone resorption. Tenth International Conference on Calcium Regulating Hormones and Eleventh Annual Meeting of the American Society for Bone and Mineral Res, Montréal, Québec, Canada, September 9–14, 1989, J Bone Miner Res, 4
Cited by
Items 101–200 of 237
Fleisch, H. A. (1996) · Osteoporosis International · doi:10.1007/bf01623942 · Cited by 45
Self-citationReginster, J., Felsenberg, D., Cooper, C. C., Stakkestad, J. A., Miller, P. D., Kendler, D. L., Adami, S., McClung, M. R., Bolognese, M. A., Civitelli, R., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1957-6 · Cited by 41
“Ibandronate is a highly potent, nitrogen-containing bisphosphonate, with greater antiresorptive efficacy than either alendronate or risedronate in animal models [ 38 , 39, 40, 41].”
BackgroundOwens, J., Fuller, K., & Chambers, T. J. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199707)172:1<79::aid-jcp9>3.0.co;2-a · Cited by 40
Fleisch, H. A., Reszka, A. A., Rodan, G. A., & Rogers, M. J. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1/50180-3 · Cited by 39
Self-citationBisphosphonates: Mechanisms of Action and Clinical Use
Fleisch, H. A. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77991-6_11 · Cited by 43
Self-citationRecent Developments in Bisphosphonate Therapy
Silverman, S. L., & Maricic, M. J. (2007) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.12.003 · Cited by 41
Cruz, J. C., Alsina, M., Craig, F. E., Yoneda, T., Anderson, J. L., Dallas, M., & Roodman, G. D. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00618-x · Cited by 37
“, the mevalonate pathway) and affect cell processes such as apoptosis and the intracellular signaling of key regulatory proteins in tumor cells and in the bone marrow microenvironment [9].”
BackgroundDiel, I., Weide, R., Köppler, H., Antràs, L., Smith, M. R., Green, J., Wintfeld, N., Neary, M. P., & Duh, M. S. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0553-7 · Cited by 36
“The high potency of these agents has been demonstrated in trials versus earlier generation intravenous regimens [13, 24 ].Therefore, ibandronate and zoledronic acid can be administered at lower doses, thereby reducing intravenous infusion times [1].”
BackgroundEffects of ibandronate on bone quality: Preclinical studies
Bauss, F., & Dempster, D. W. (2006) · Bone · doi:10.1016/j.bone.2006.08.002 · Cited by 35
Self-citationRecker, R. R., Ste‐Marie, L., Langdahl, B. L., Czerwinski, E. J., Bonvoisin, B., Masanauskaite, D., Rowell, L., & Felsenberg, D. (2009) · Bone · doi:10.1016/j.bone.2009.11.004 · Cited by 35
“Ibandronate is a potent, nitrogen-containing bisphosphonate that can be administered orally or intravenously with extended dosing intervals [1,2].”
BackgroundShort- and Long-Term Effects of Ibandronate Treatment on Bone Turnover in Paget Disease of Bone
Woitge, H. W., Oberwittler, H., Heichel, S., Grauer, A., Ziegler, R., & Seibel, M. J. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.5.684 · Cited by 33
Agnello, K. A., Trumble, T. N., Chambers, J. N., Seewald, W., & Budsberg, S. C. (2005) · American Journal of Veterinary Research · doi:10.2460/ajvr.2005.66.1487 · Cited by 31
Yu, X., Schøller, J., & Foged, N. T. (1996) · Bone · doi:10.1016/s8756-3282(96)00184-6 · Cited by 36
Local dual delivery therapeutic strategies: Using biomaterials for advanced bone tissue regeneration
Wani, T. U., Khan, R. S., Rather, A. H., Beigh, M. A., & Sheikh, F. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.029 · Cited by 31
Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders
Ghinoi, V., & Brandi, M. L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.11.1643 · Cited by 30
“• Inhibition of the release of 45Ca and of the urinary excretion of tetracycline in prelabelled rats [7,8].”
BackgroundWüster, C., Schöter, K.-H., Thiébaud, D., Manegold, C., Krahl, D., Clemens, M., Ghielmini, M. E. G., JAEGER, P., & SCHARLA, S. H. (1993) · Bone and Mineral · doi:10.1016/s0169-6009(08)80219-x · Cited by 31
Once-monthly Ibandronate for postmenopausal Osteoporosis: Review of a new dosing regimen
Pyon, E. Y. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.04.006 · Cited by 30
Body, J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10136-8 · Cited by 29
Solid-state NMR of bisphosphonates adsorbed on hydroxyapatite
Großmann, G., Grossmann, A., Ohms, G., Breuer, E., Chen, R., Golomb, G., Cohen, H., Hägele, G., & Classen, R. (2000) · Magnetic Resonance in Chemistry · Cited by 28
Phosphate depletion in the rat: Effect of bisphosphonates and the calcemic response to PTH
Jara, A., Lee, E., Stauber, D. J., Moatamed, F., Felsenfeld, A. J., & Kleeman, C. R. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00395.x · Cited by 28
Treatment of malignant hypercalcaemia
Esbrit, P., & Hurtado, J. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.5.521 · Cited by 28
“The potency of ibandronate to inhibit osteoclast-mediated bone resorption was 500-, 50-, 10- and 2-fold higher than that of clodronate, pamidronate, alendronate and risedronate, respectively [43].”
Bauss, F., & Schimmer, R. C. (2006) · PubMed Central · Cited by 37
Self-citationIbandronate: Pharmacology and preclinical studies
Russell, R. G. G. (2006) · Bone · doi:10.1016/j.bone.2006.01.151 · Cited by 28
Berenson, J. R. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.03.001 · Cited by 28
Ibandronate treatment in Paget’s disease of bone
Grauer, A., Heichel, S., Knaus, J., Dosch, E., & Ziegler, R. (1999) · Bone · doi:10.1016/s8756-3282(99)00072-1 · Cited by 27
Lawson, M. A., Ebetino, F. H., Mazur, A., Chantry, A., Paton‐Hough, J., Evans, H., Lath, D., Tsoumpra, M. K., Lundy, M. W., Dobson, R. L. M., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3138 · Cited by 26
“Such compounds, like RIS, have a more rapidly reversible effect on reducing bone turnover compared with longer-acting bisphosphonates such as ALN and ZOL.”
BackgroundYang, X., Chan, Y. H., Muthukumaran, P., DasDe, S., Teoh, S. H., & Lee, T. (2011) · Bone · doi:10.1016/j.bone.2011.02.007 · Cited by 27
“Ibandronate has been proven effective in inhibiting bone resorption at considerably lower doses than other bisphosphonates in both rats [11] and ovariohysterectomized dogs [12,13].”
BackgroundPro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo
Richards, P. J., Amos, N., Williams, A. S., & Williams, B. D. (1999) · Rheumatology · doi:10.1093/rheumatology/38.10.984 · Cited by 26
α-AMINO ACID DERIVED BISPHOSPHONATES. SYNTHESIS AND ANTI-RESORFTIVE ACTIVITY
Mizrahi, D. M., Waner, T., & Segall, Y. (2001) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426500108045257 · Cited by 25
Gordon, D. H. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.014 · Cited by 25
Epstein, S., & Zaidi, M. (2005) · Bone · doi:10.1016/j.bone.2005.05.007 · Cited by 27
“With regard to its antiresorptive properties, ibandronate inhibits bone resorption in a dose-dependent manner and, owing to its chemical configuration at the R2 position, is 2-, 10-, and 50-times more potent in vivo than risedronate, alendronate, and pamidronate, respectively, and 500-times more potent than clodronate…”
BackgroundInfluentialEffect of Bisphosphonates on the Increase in Bone Resorption Induced by a Low Calcium Diet
Antic, V., Fleisch, H. A., & Mühlbauer, R. C. (1996) · Calcified Tissue International · doi:10.1007/bf02509445 · Cited by 25
Self-citationGladysz, R., dos Santos, F. M., Langenaeker, W., Thijs, G., Augustyns, K., & Winter, H. L. D. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0268-9 · Cited by 26
“Focusing in first instance on the farnesyl diphosphate synthase target, the hit retrieved from the Enamine HTS library for this enzyme was Z2181651281, a compound also known as ibandronic acid and described as a potent farnesyl pyrophosphate synthase inhibitor [55].”
BackgroundEberhardt, C., Schwarz, M., & Kurth, A. H. (2005) · Journal of Orthopaedic Science · doi:10.1007/s00776-005-0955-z · Cited by 24
Einführung in die Bisphosphonate: Geschichte und Wirkungsmechanismen
Fleisch, H. A. (2007) · Der Orthopäde · doi:10.1007/s00132-006-1040-9 · Cited by 23
Self-citationYates, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2179-3 · Cited by 26
Manabe, T., Mori, S., Mashiba, T., Kaji, Y., Iwata, K., Komatsubara, S., & Yamamoto, T. (2012) · Calcified Tissue International · doi:10.1007/s00223-011-9563-4 · Cited by 24
Juraschek, M., Seibel, M. J., Woitge, H. W., Krempien, B., & Bauss, F. (2000) · Bone · doi:10.1016/s8756-3282(00)00259-3 · Cited by 23
Self-citationTREATMENT OF OSTEOPOROSIS WITH BISPHOSPHONATES
Watts, N. B. (1994) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)00357-4 · Cited by 25
Guay, D. R. P. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.5.655 · Cited by 22
“In vivo, ibandronate is 2–500-fold more potent than other bisphosphonates as an inhibitor of bone resorption.(7) In several animal models, ibandronate also increased or preserved bone mass and density, prevented deterioration of bone architecture, preserved bone strength, and maintained or restored bone quality.”
BackgroundEpstein, S., Delmas, P. D., Emkey, R. D., Wilson, K., Hiltbrunner, V., & Schimmer, R. C. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.01.011 · Cited by 22
Bisphosphonates in the treatment of bone metastases
Finley, R. S. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31534 · Cited by 22
IBANDRONATE: A POTENT NEW BISPHOSPHONATE IN THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS
Papapoulos, S. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10518.x · Cited by 24
Sakai, S., Takeda, S., Sugimoto, M., Shimizu, M., Shimonaka, Y., Yogo, K., Hashimoto, J., Bauss, F., & Endo, K. (2015) · Bone · doi:10.1016/j.bone.2015.08.004 · Cited by 21
Self-citationInhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
Jang, Y., Sohn, H. M., Ko, Y. J., Hyun, H., & Lim, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010434 · Cited by 21
Bisphosphonates in development for metabolic bone disease
Sietsema, W. K., & Ebetino, F. H. (1994) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.3.12.1255 · Cited by 21
The Treatment of Hormone Refractory Prostate Cancer
Heidenreich, A., & Schrader, A. J. (2003) · EAU Update Series · doi:10.1016/s1570-9124(03)00008-4 · Cited by 20
Renal Safety of Intravenous Ibandronic Acid in Breast Cancer Patients with Metastatic Bone Disease
Lyubimova, N. V., Кушлинский, Н. Е., Lichinitser, M. R., & Schlosser, K. (2003) · Clinical Drug Investigation · doi:10.2165/00044011-200323110-00003 · Cited by 20
Abdou, W. M., Ganoub, N. A., Fahmy, A. F. M., & Shaddy, A. A. (2005) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-005-0403-y · Cited by 19
Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits
Pennypacker, B. L., Oballa, R. M., Levesque, S., Kimmel, D. B., & Duong, L. T. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-344 · Cited by 19
Treating Osteoporosis with Bisphosphonates and Addressing Adherence: A Review of Oral Ibandronate
Chesnut, C. H. (2006) · Drugs · doi:10.2165/00003495-200666100-00004 · Cited by 22
Enhanced Oral Absorption of Ibandronate via Complex Formation with Bile Acid Derivative
Park, J. W., Hwang, S. R., Jeon, O., Moon, H. T., & Byun, Y. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23413 · Cited by 18
Neutzsky-Wulff, A. V., Sørensen, M. G., Kocijancic, D., Leeming, D. J., Dziegiel, M. H., Karsdal, M. A., & Henriksen, K. (2010) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-11-109 · Cited by 23
“Finally, ibandronate, a nitrogen-containing bisphosphonate [43], was tested to evaluate the effect of general osteoclast inhibition.”
Mayahara, M., & Sasaki, T. (2003) · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · doi:10.1002/ar.a.10092 · Cited by 23
Ibandronic Acid: A Review of its Use in the Treatment of Bone Metastases of Breast Cancer
McCormack, P. L., & Plosker, G. L. (2006) · Drugs · doi:10.2165/00003495-200666050-00011 · Cited by 18
Halvorson, K. G., Sevcik, M. A., Ghilardi, J. R., Sullivan, L. J., Koewler, N. J., Bauss, F., & Mantyh, P. W. (2008) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2007.10.005 · Cited by 19
Self-citationBerenson, J. R. (2001) · Current Treatment Options in Oncology · doi:10.1007/s11864-001-0041-5 · Cited by 17
The Bisphosphonate Odyssey. A Journey from Chemistry to the Clinic
Graham, R., & Russell, R. G. G. (1999) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426509908039679 · Cited by 17
Nishikawa, M., Yamamoto, M., Murakami, T., Akatsu, T., Kugai, N., & Nagata, N. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.6.986 · Cited by 17
Treatment with ibandronate preserves bone in experimental tumour-induced bone loss
Kurth, A. H. A., Kim, S.-Z., Sedlmeyer, I., Hovy, L., & Bauss, F. (2000) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.82b1.0820126 · Cited by 16
Self-citationRizzoli, R., Caverzasio, J., Bauss, F., & Bonjour, J. ‐. (1992) · Bone · doi:10.1016/8756-3282(92)90077-a · Cited by 16
Self-citationThe bisphosponates: chemical characteristics, skeletal biological effects and extra-skeletal effects
Corrado, A., & Cantatore, F. P. (2011) · Reumatismo · doi:10.4081/reumatismo.2005.142 · Cited by 15
“In alcuni studi è stato verificato che il trattamento con BF stimola il reclutamento osteoclastico (6, 14), ma tale dato non è stato confermato; in numerosi modelli sperimentali, infatti, i BF inibiscono la formazione di osteoclasti da precursori midollari (15-19).”
BackgroundPrimary Hyperparathyroidism: Diagnosis and Management
Khan, A. A. (1997) · Endocrine Practice · doi:10.4158/ep.3.1.22 · Cited by 15
Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities
Reginster, J. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01292.x · Cited by 16
Osteoporosis treatment: why ibandronic acid?
Rossini, M., Orsolini, G., Adami, S., Kunnathully, V., & Gatti, D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.795949 · Cited by 15
“The potency of ibandronate is because of its structural attributes (Box 1), with the addition of a tertiary nitrogen group on the R2 side chain, making the drug 2-, 50-, and 500-fold more potent than alendronate, pamidronate, and clodronate, respectively [10].”
BackgroundMcHugh, N. A., Vercesi, H. M., Egan, R. W., & Hey, J. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00102.2002 · Cited by 14
Ibandronate: The Evolution of a Once-a-Month Oral Therapy for Postmenopausal Osteoporosis
Dempster, D. W., & Bolognese, M. A. (2006) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2005.09.004 · Cited by 15
Once-monthly oral ibandronate in postmenopausal osteoporosis: Translation and updated review
Rossini, M., Viapiana, O., Gatti, D., & Adami, S. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.07.018 · Cited by 15
Bisphosphonate activation of crystallized bioglass scaffolds for enhanced bone formation
Thavornyutikarn, B., Wright, P., Feltis, B., Kosorn, W., & Turney, T. W. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.109937 · Cited by 12
Roelofs, A. J., Ebetino, F. H., Reszka, A. A., Russell, R. G. G., & Rogers, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00095-1 · Cited by 13
Gelder, J. M. V., Breuer, E., Schlossman, A., Ornoy, A., Mönkkönen, J., Similä, J., Klenner, T., Stadler, H., Krempien, B., Patlas, N., et al. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960429h · Cited by 12
Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate
Simonelli, C., & Burke, M. S. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x104867 · Cited by 12
From Polyphosphates to Bisphosphonates and Their Role in Bone and Calcium Metabolism
Fleisch, H. A. (1999) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-58444-2_10 · Cited by 16
Self-citationQiu, L., Lin, J., Wang, L., Cheng, W. D., Cao, Y., Liu, X., & Luo, S. (2013) · Australian Journal of Chemistry · doi:10.1071/ch13194 · Cited by 11
Comment on the American Association of Oral and Maxillofacial Surgeons Statement on Bisphosphonates
Zahrowski, J. J. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2007.04.004 · Cited by 11
Intravenous bisphosphonates for postmenopausal osteoporosis.
Mottaghi, P. (2010) · PubMed Central · Cited by 12
Progression of Efficacy with Ibandronate: A Paradigm for the Development of New Bisphosphonates
Zaidi, M., Epstein, S., Harris, S. T., Kohles, J. D., & Chesnut, C. H. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.052 · Cited by 11
Jarvis, M. F., Burns, C. J., Pauls, H. W., Assal, A. A., Kim, J. S., Cheney, D. L., & Youssefyeh, R. D. (1993) · Calcified Tissue International · doi:10.1007/bf00310202 · Cited by 11
“Consequently, a number of bisphosphonate analogs have been shown to effectively inhibit bone resorption in vivo [5, 6] and appear to be of some therapeutic utility in the treatment of osteoporosis [3, 5-9].”
BackgroundFrick, K. K., Asplin, J. R., Culbertson, C. D., Granja, I., Krieger, N. S., & Bushinsky, D. A. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00680.2013 · Cited by 10
Felsenfeld, A. J., Jara, A., Avedian, G., & Kleeman, C. R. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00259.x · Cited by 9
Efficacy and safety of ibandronate in the treatment of neoplastic bone disease
Pecherstorfer, M. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.11.2341 · Cited by 9
Bisphosphonates: Mechanisms of Action
Fleisch, H. A. (1998) · Advances in organ biology · doi:10.1016/s1569-2590(08)60154-8 · Cited by 11
Self-citationAnimal Models in Bone Research
Kimmel, D. B. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-56192-9_4 · Cited by 10
Fleisch, H. A. (2000) · Elsevier eBooks · doi:10.1016/b978-012260371-6.50004-5 · Cited by 8
Self-citationBiochemical bone turnover markers are useful tools to assess changes in bone metabolism in marmosets
Angeliewa, A., Budde, M., Schlachter, M., Hoyle, N. R., & Bauss, F. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0469-8 · Cited by 7
“The ibandronate regimen was derived from a study conducted in young growing rats, in which ibandronate significantly inhibited non-stimulated (endogenous) bone resorption within 3 to 7 days [6].”
MethodSelf-citationBeyond daily dosing: Clinical experience
Cooper, C. C. (2006) · Bone · doi:10.1016/j.bone.2006.01.152 · Cited by 7
“Ibandronate, a potent nitrogen-containing bisphosphonate specifically developed for use with extended dose-free intervals, has been subjected to a substantial preclinical development program [17,18].”
BackgroundChiu, W., Lin, C., Yang, W., Tsai, K., & Reginster, J. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05127-y · Cited by 7
Müller, R., & Recker, R. R. (2007) · Bone · doi:10.1016/j.bone.2007.08.004 · Cited by 7
“For example, an early study with ibandronate in rats showed that, even at the highest dose (1 mg/kg), there were no inhibitions of mineralization and no signs of delay or inhibition of cartilage calcification [19].”
ResultHypercalcaemia in patients with cancer: aetiology and treatment
Heys, S. D., Smith, I. C., & Eremin, O. (1998) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(98)91589-x · Cited by 7
Morohashi, T. (2002) · Bioscience and Microflora · doi:10.12938/bifidus1996.21.21 · Cited by 7
Hiraga, T., Takada, M., Nakajima, T., & Ozawa, H. (1996) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(96)90492-9 · Cited by 7
Basic Biology of Bisphosphonates
Fleisch, H. A. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50017-9 · Cited by 7
Self-citationBurckhardt, P. (1997) · Cancer · Cited by 7
Fernández, D., Ramis, R., Ortega‐Castro, J., Casasnovas, R., Vilanova, B., & Frau, J. (2017) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-017-0034-5 · Cited by 6
Mehta, S., Wang, K., Chen, P., Fan, Z., Ahmida, A., Kalajzić, Ž., & Yadav, S. K. (2023) · European Journal of Orthodontics · doi:10.1093/ejo/cjad001 · Cited by 7
Sunyecz, J. A., & Derman, R. J. (2007) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000266070.47052.52 · Cited by 7
“Ibandronate is 2 and 10 times more potent than risedronate and alendronate, respectively, as found by inhibition of arotinoid-stimulated bone resorption in a rat model assay (61); this potency is the result of specific molecular characteristics that enhance skeletal binding and prevention of hydroxyapatite crystal gro…”
BackgroundHothorn, L. A., & Bauss, F. (2004) · Drug Information Journal · doi:10.1177/009286150403800107 · Cited by 6
Self-citationSynergistic local drug delivery in a piglet model of ischemic osteonecrosis: a preliminary study
Zou, Y., Fisher, P. D., Horstmann, J. K., Talwalkar, V. R., Milbrandt, T. A., & Puleo, D. A. (2015) · Journal of Pediatric Orthopaedics B · doi:10.1097/bpb.0000000000000213 · Cited by 5
Monzem, S., Ballester, R. Y., Javaheri, B., Poulet, B., Sônego, D. A., Pitsillides, A. A., & de Souza, R. L. (2020) · Bone & Joint Open · doi:10.1302/2633-1462.19.bjo-2020-0117.r1 · Cited by 5
Bisphosphonates and osteoporosis
Sørensen, O. H., Storm, T., Thamsborg, G., Sørensen, H. A., Kollerup, G., Steiniche, T., Melsen, F., & Genant, H. K. (1993) · Osteoporosis International · doi:10.1007/bf01621913 · Cited by 5
Metadata
- Authors
- Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H.
- Affiliations
- University of Bern (CH)
- Boehringer Mannheim, Mannheim, Germany
- Corresponding author
- Mühlbauer, R.C.
- ORCID
- Janner, M.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-09-01
- Volume
- 6
- Issue
- 9
- Pages
- 1003-1011
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2012291531
- Cited by
- 239
- References
- 30
- Citations by year
- 2023: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, bone resorption inhibition, osteoclasts, risedronate, alendronate, pamidronate, clodronate, bone mass, bone histomorphometry
- MeSH terms
- Risedronic Acid, Pamidronate, Ibandronic Acid, Animals, Benzoates, Bone Resorption, Calcium, Clodronic Acid, Diphosphonates, Injections, Intravenous, Osteoclasts, Retinoids, Etidronic Acid, Spectrophotometry, Atomic, Tetracycline, Thyroxine, Alendronate, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.